drugset / Trial / NCT02427841

Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

NCT02427841 ↗

NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies how well nab-paclitaxel and gemcitabine hydrochloride followed by radiation therapy before surgery work in treating patients with pancreatic cancer that can be removed by surgery. Chemotherapy drugs, such as nab-paclitaxel and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving nab-paclitaxel, gemcitabine hydrochloride, and radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

Timeline

Start
2016-01-21
Primary completion
2019-11-12
Completion
2022-12-12

Outcome

Missed primary endpoint

registry p = .404; binomial 42 (95% CI 20 to 67) NCT02427841 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule — Intravenous
Subject Nab-paclitaxel Small molecule — Intravenous
Subject fluorouracil Small molecule — Intravenous